Cambridge Cognition joins Imperial College-led NHS study bringing earlier Alzheimer’s diagnosis into primary care
Cambridge Cognition joins an Imperial College-led NHS study exploring how to bring earlier Alzheimer’s diagnosis into primary care.
Measuring speech in schizophrenia spectrum disorders
A practical guide to speech features, elicitation tasks and study design
Measuring speech in schizophrenia spectrum disorders Read More »
First new CANTAB® product features developed & launched from the landmark INTUITION project
First new CANTAB® product features developed & launched from the landmark INTUITION project Cambridge Cognition (AIM: COG), the neuroscience technology company, announces two new product features for its CANTAB digital cognitive assessments derived from analysis of data from the INTUITION project. ​​​Application of Expanded Normative Dataset – Increased Sensitivity and Accuracy of CANTAB® ​The first
C2N Diagnostics Expands Global Partnerships in United Kingdom on World Alzheimer’s Day, Joins Cambridge Cognition and The Alzheimer’s Trust to Improve Alzheimer’s Disease Diagnosis
Collaboration integrates cognitive assessment, proprietary blood test, national phlebotomy and MRI infrastructure to accelerate patient diagnosis and care pathways throughout the UK.
Integrating Blood-Based Biomarkers & Digital Cognitive Assessments to Accelerate Brain Health Research
The Convergence: Integrating Blood Biomarker Tests and Digital Cognition to Accelerate Alzheimer’s Research The paradigm for diagnosing and monitoring Alzheimer’s disease (AD) is shifting from relying on clinical symptoms to incorporating definitive biological evidence of amyloid and tau proteinopathy. As discussed in our recent joint webinar with C2N Diagnostics and the AI-Mind project, combining blood
Bringing Trial Activities to the Participant – Lessons from the RADIAL Proof-of-Concept Trial
Bringing Trial Activities to the Participant Lessons from the RADIAL Proof-of-Concept Trial The move toward more participant-centric clinical research has taken an important step forward. At the Clinical Pharmacology & Therapeutics journal, the first papers from the RADIAL trial, the flagship study of the Trials@Home project have now been published, offering valuable insights into how clinical research
Speech Analysis as an Objective Biomarker in MDD Trials Speech Biomarkers for Alzheimer’s Disease Show Promise Across Multiple Languages
Speech Biomarkers for Alzheimer’s Disease Show Promise Across Multiple Languages The search for reliable, accessible biomarkers for early detection of cognitive decline has taken an important step forward. At AAIC 2025, our team presented data demonstrating that speech and language patterns can serve as valid digital biomarkers for Mild Cognitive Impairment (MCI) and Alzheimer’s disease
CTAD | Posters & Presentations
CTAD | Posters & Presentations Hilton San Diego Bayfront, 1 Park Boulevard – San Diego, CA 92101 | 1-4th December We’re excited to announce we are attending the 18th Clinical Trials on Alzheimer’s Disease (CTAD) This year’s Clinical Trials on Alzheimer’s Disease (CTAD) conference brings together global leaders advancing research and innovation in Alzheimer’s and
CTAD | Posters & Presentations Read More »
DIS | Posters & Presentations
DIS | Posters & Presentations Pfizer Innovation Research (PfIRe Lab) 1 Portland St Cambridge, MA 02139 | 5th November 09:00am – 5:30pm PST We’re excited to announce that our team will be attending the 8th Annual Digital Implementation Summit This year’s Digital Implementation Summit brings together global leaders driving the transformation of clinical development from
DIS | Posters & Presentations Read More »
Closing the Gap – Speech Analysis as an Objective Biomarker in MDD Trials
Closing the Gap Speech Analysis as an Objective Biomarker in MDD Trials The development of new therapies for Central Nervous System (CNS) disorders, particularly Major Depressive Disorder (MDD), is fundamentally challenged by the subjectivity and limitations of current assessment tools. Traditional measures, which often rely on patient self-reports or clinician ratings, frequently fail to capture
Closing the Gap – Speech Analysis as an Objective Biomarker in MDD Trials Read More »
